Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study)
Authors:
- Bernard CombeBCBernard Combe
- Gary SwergoldGSGary Swergold
- James McLayJMJames McLay
- Timothy McCarthyTMTimothy McCarthy
- Cristiano ZerbiniCZCristiano Zerbini
- Paul EmeryPEPaul Emery
- Laurine ConnorsLCLaurine Connors
- Amarjot KaurAKAmarjot Kaur
- Sean CurtisSCSean Curtis
- Loren LaineLLLoren Laine
- Christopher P. CannonCCChristopher P. Cannon
Open Access
- 30 January 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 48 (4) , 425-432
Abstract
Objective. To compare cardiovascular (CV) and other safety and efficacy parameters of etoricoxib 60 and 90 mg, and diclofenac 150 mg. Methods. This double-blind study randomized OA patients to etoricoxib 90 mg, then to 60 mg once daily vs diclofenac 75 mg twice daily; RA patients were randomized to etoricoxib 90 mg once daily or diclofenac 75 mg twice daily. The primary endpoint was non-inferiority of etoricoxib vs diclofenac for thrombotic CV events (95% CI upper bound of hazard ratio Results. A total of 23 504 patients were randomized with mean treatment duration from 19.4 to 20.8 months. The thrombotic CV risk hazard ratio (HR) (etoricoxib to diclofenac) was 0.96 (95% CI 0.81, 1.15), consistent with non-inferiority of etoricoxib to diclofenac. The cumulative gastrointestinal (GI)/liver adverse events (AEs) discontinuation rate was significantly lower for etoricoxib than diclofenac in each patient cohort; HR (95% CI) of 0.46 (0.39, 0.54), 0.52 (0.42, 0.63) and 0.49 (0.39, 0.62) for the 60 mg OA, 90 mg OA and RA cohorts. The maximum average change in systolic blood pressure (BP) with etoricoxib was 3.4–3.6 mmHg (diastolic BP: 1.0–1.5 mmHg), while diclofenac produced a maximum average change of 0.9–1.9 mmHg (diastolic BP: 0.0–0.5 mmHg). Both agents resulted in similar efficacy regardless of etoricoxib dose. Conclusion. Long-term etoricoxib use is associated with a risk of thrombotic CV events comparable with that of diclofenac. Compared with diclofenac, etoricoxib demonstrated a greater risk of renovascular AEs, but a more favourable GI/liver tolerability profile.Keywords
This publication has 30 references indexed in Scilit:
- Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II)Annals of the Rheumatic Diseases, 2008
- Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Study Program: Cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritisAmerican Heart Journal, 2006
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- EtoricoxibDrugs of Today, 2004
- Series Introduction: COX in a crystal ball: current status and future promise of prostaglandin researchJournal of Clinical Investigation, 2001
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995
- A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressureArchives of internal medicine (1960), 1993
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988
- The clinical significance of inhibition of renal prostaglandin synthesisKidney International, 1987